Menlo Ventures Invests in Vilya, Inc. to Advance AI-Driven Drug Development

Menlo Ventures, a venture capital firm recognized for supporting innovative entrepreneurs, has announced a substantial investment in Vilya, Inc., a biotechnology company dedicated to developing a new class of medicines that specifically target disease biology. This investment comes at a time when concerns about the risks associated with generative AI are rising, particularly as it impacts various sectors, including healthcare and pharmaceuticals.

Vilya has successfully expanded its Series A funding round to $71 million, led by ARCH Venture Partners, with additional participation from NVIDIA’s NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. The funding will accelerate the growth of Vilya’s proprietary computational drug design platform and its pipeline of innovative macrocycles targeting disease biology.

Cyrus Harmon, Ph.D., CEO of Vilya, commented, “The support from these esteemed investors will significantly enhance our generative AI platform, allowing us to broaden the diversity of macrocycles we can design and develop, as well as expand the targets we can pursue. This funding also enables us to advance our designed macrocycles to clinical development candidates more quickly.”

Vilya employs advanced computational techniques to design novel macrocycles with atomic-level precision and improved drug-like properties. Unlike traditional drug discovery methods, which often rely on random screening and a limited exploration of chemical compounds, Vilya’s technology enables precise targeting of disease biology in areas where innovative treatments are urgently needed.

Following this investment, Greg Yap, a Partner at Menlo Ventures, will join Vilya’s board. He noted, “Vilya empowers experienced drug developers with cutting-edge AI technology, unlocking this valuable yet challenging drug class. Their focus on macrocycles and a high-throughput platform allows for rapid iterations from prediction to candidate drug testing, accelerating the development of life-saving medicines.”

Founded in 2022 by leading scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., Vilya is assembling a world-class team with extensive expertise in computational drug discovery, chemistry, biology, and clinical development. The leadership team includes Cyrus Harmon (CEO), Katerina Leftheris (CSO), Patrick Salveson (Co-Founder and CTO), and Inca Dieterich (Co-Founder and VP of Business Development).

Focusing on macrocycles—complex yet promising drugs—Vilya aims to streamline the design and development process. While macrocycles have the potential to target clinically relevant protein interactions, significant challenges in drug development persist. With this new funding, Vilya plans to expedite the transition from macrocycle design to clinical development, offering new hope for patients in need of innovative therapies.

By leveraging generative AI in drug design, Vilya is poised to make a significant impact in the biotechnology and healthcare sectors, paving the way for breakthroughs in treating diseases that still lack effective solutions.